Technical Analysis for AMRX - Amneal Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 6.53 -1.88% -0.13
AMRX closed down 1.77 percent on Monday, May 6, 2024, on 80 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New Uptrend Bullish -1.88%
Jack-in-the-Box Bullish Bullish Swing Setup -1.88%
Upper Bollinger Band Walk Strength -1.88%
Earnings Movers Other -1.88%
Inside Day Range Contraction -1.88%
Above Upper BB Strength -1.88%
Overbought Stochastic Strength -1.88%
Upper Bollinger Band Touch Strength -1.88%
New 52 Week Closing High Bullish -3.62%
Expansion Breakout Bullish Swing Setup -3.62%

   Recent Intraday Alerts

Alert Time
Down 2 % about 1 hour ago
60 Minute Opening Range Breakdown about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
Down 1% about 3 hours ago
Fell Below Upper Bollinger Band about 4 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amneal Pharmaceuticals, Inc. Description

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Drugs Pharmaceutical Products Parkinson's Disease Drug Products Treatment Of Parkinson's Disease Headache Migraine Generic Drug Migraine Headache Treatment Of Migraine Migraine Headaches

Is AMRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.9
52 Week Low 1.74
Average Volume 1,689,318
200-Day Moving Average 4.86
50-Day Moving Average 5.77
20-Day Moving Average 5.81
10-Day Moving Average 6.10
Average True Range 0.32
RSI (14) 71.75
ADX 26.88
+DI 32.12
-DI 9.24
Chandelier Exit (Long, 3 ATRs) 5.94
Chandelier Exit (Short, 3 ATRs) 6.14
Upper Bollinger Bands 6.61
Lower Bollinger Band 5.01
Percent B (%b) 1.03
BandWidth 27.44
MACD Line 0.19
MACD Signal Line 0.07
MACD Histogram 0.1162
Fundamentals Value
Market Cap 2.04 Billion
Num Shares 307 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 110.83
Price-to-Sales 0.72
Price-to-Book 5.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.09
Resistance 3 (R3) 7.11 6.97 7.02
Resistance 2 (R2) 6.97 6.86 6.97 6.99
Resistance 1 (R1) 6.81 6.79 6.75 6.80 6.97
Pivot Point 6.68 6.68 6.65 6.67 6.68
Support 1 (S1) 6.52 6.57 6.45 6.50 6.33
Support 2 (S2) 6.38 6.50 6.38 6.31
Support 3 (S3) 6.22 6.38 6.28
Support 4 (S4) 6.21